Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations
A small (and complex) study of non-V600 BRAF mutations suggests efficacy for MEK ± BRAF inhibition but not single agent BRAF inhibition. 19% of melanoma-associated BRAF driver mutations are non-V600 (GENIE v5.0).
Patients with rare BRAF mutations can respond to targeted therapy, however, efficacy seems to be lower compared with V600E mutated melanoma. Combination BRAFi/MEKi seems to be the best regimen for both V600 and non-V600 mutations. Yet interpretation should be done with care because of the heterogeneity of patients with small sample sizes for some of the reported mutations.